Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Pfizer Inc at Handelsbanken Life Science Innovation Day (Virtual) Transcript

Aug 24, 2022 / 02:30PM GMT
Mattias HÃ;ggblom;Christopher J. Stevo
Handelsbanken Capital Markets AB, Research Division - Research Analyst;Pfizer Inc. - Senior

¤ -

So good morning for those of you in the U.S. and good afternoon for those of you joining here in Europe. So my name is Mattias Häggblom. I'm Sector Head of Healthcare Research here at Handelsbanken, and welcome to the final but perhaps most important session at our second annual Life Science and Innovation Day.

It's a great honor to welcome Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical at Pfizer, as our keynote speaker to this year's Innovation Day. And what better fits by ending an event focused on innovation to bring a company who played a crucial role and continues to do so in the fight against COVID-19, both with the vaccine but also an antiviral.

Before I start my discussion with Mikael, I'm going to hand over to Chris Stevo, Head of IR at Pfizer, who's going to help us with some of the disclaimers around forward-looking statements. Chris, over to you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot